Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor

Metabolic Engineering

Volumn 14, Issue 5, 2012, Pages 521-527

  Zhang, Chunyu ^a   Liu, Long ^a   Teng, Liping ^a   Chen, Jinghua ^a   Liu, Jian ^b   Li, Jianghua ^a   Du, Guocheng ^a   Chen, Jian ^a  

^a JIANGNAN UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bioengineered heparin; Chemical structure; Escherichia coli K5; Heparosan; Metabolic engineering; Molecular weight

Indexed keywords

ALTERNATIVE SOURCE; BACTERIA STRAIN; BATCH BIOREACTORS; BIOENGINEERED HEPARIN; CO-EXPRESSION; E. COLI; FED-BATCH CULTURES; HEPAROSAN; PATHOGENIC BACTERIUM; RECOMBINANT E. COLI; RECOMBINANT STRAINS; SHAKE FLASKS; URINARY TRACT INFECTIONS; WEIGHT-AVERAGE MOLECULAR WEIGHT;

BACTERIA; BATCH CELL CULTURE; BIOCHEMISTRY; BIOREACTORS; BIOSYNTHESIS; BOTTLES; CLONING; GENES; METABOLIC ENGINEERING; MOLECULAR WEIGHT; POLYSACCHARIDES; STRAIN; STRUCTURE (COMPOSITION);

ESCHERICHIA COLI;

DISSOLVED OXYGEN; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BIOSAFETY; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CHEMICAL STRUCTURE; ESCHERICHIA COLI; FED BATCH CULTURE; GENE EXPRESSION; METABOLIC ENGINEERING; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PLASMID; PRIORITY JOURNAL;

DISACCHARIDES; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GLYCOSYLTRANSFERASES; HEPARIN; METABOLIC ENGINEERING; N-ACETYLGLUCOSAMINYLTRANSFERASES; OXYGEN; PLASMIDS; URIDINE DIPHOSPHATE GLUCOSE DEHYDROGENASE;

ESCHERICHIA COLI;

EID: 84865600352     PISSN: 10967176     EISSN: 10967184     Source Type: Journal    
DOI: 10.1016/j.ymben.2012.06.005     Document Type: Article

References (39)

1. 2 pathway in Escherichia coli BL21(DE3). Metab. Eng. 2009, 11:139-147.
2. Baik J.Y., Gasimli L., Yang B., Datta P., Zhang F., Glass C.A., Esko J.D., Linhardt R.J., Sharfstein S.T. Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. Metab. Eng. 2012, 14:81-90.
3. Bhaskar U., Sterner E., Hickey A.M., Onishi A., Zhang F.M., Dordick J.S., Linhardt R.J. Engineering of routes to heparin and related polysaccharides. Appl. Microbiol. Biotechnol. 2012, 93:1-16.
4. Bitter T., Muir M. A modified uronic acid carbazole reaction. Anal. Biochem. 1962, 4:330-334.
5. DeAngelis P.L., Gunay N.S., Toida T., Mao W.J., Linhardt R.J. Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohyd. Res. 2002, 337:1547-1552.
6. Folkman J., Weisz P.B., Joullie M.M., Li W.W., Ewing W.R. Control of angiogenesis with synthetic heparin substitutes. Sci 1989, 243:1490-1493.
7. Hodson N., Griffiths G., Cook N., Pourhossein M., Gottfridson E., Lind T., Lidholt K., Roberts I.S. Identification that KfiA, a protein essential for the biosynthesis of the Escherichia coli K5 capsular polysaccharide, is an a-UDP-GlcNAc glycosyltransferase. J. Biol. Chem. 2000, 275:27311-27315.
8. Jongsareejit B., Bhumiratana A., Morikawa M., Kanaya S. Cloning of hyaluronan synthase (sz-has) gene from Streptococcus zooepidemicus in Escherichia coli. Sci. Asia 2007, 33:389-395.
9. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
10. Kuberan B., Beeler D.L., Lech M., Wu Z.L., Rosenberg R.D. Chemoenzymatic synthesis of classical and non-classical anticoagulant heparin sulfate polysaccharides. J. Biol. Chem. 2003, 278:52613-52621.
11. Kuberan B., Beeler D.L., Lech M., Wu Z.L., Rosenberg R.D. Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat. Biotechnol. 2003, 21:1343-1346.
12. Laremore T.N., Zhang F.M., Dordick J.S., Liu J., Linhardt R.J. Recent progress and applications in glycosaminoglycan and heparin research. Curr. Opin. Chem. Biol. 2009, 13:633-640.
13. Laurencin C.T., Nair L. The FDA and safety-beyond the heparin crisis. Nat. Biotechnol. 2008, 26:621-623.
14. Legoux R., Lelong P., Jourde C., Feuillerat C. N-acetyl-heparosan lyase of Escherichia coli K5: gene cloning and expression. J. Bacteriol. 1996, 178:7260-7264.
15. Lin Y.L., Lei H.Y., Lin Y.S., Yeh T.M., Chen S.H., Liu H.S. Heparin inhibits dengue-2 virus infection of five human liver cell lines. Antiviral. Res. 2002, 56:93-96.
16. Lindahl U., Li J.P., Kusche-Gullberg M., Salmivirta M., Alaranta S., Veromaa T., Emeis J., Roberts I., Taylor C., Oreste P. Generation of "Neoheparin" from E. coli K5 capsular polysaccharide. J. Med. Chem. 2005, 48:349-352.
17. Lidholt K., Riesenfeld J., Jacobsson K.G., Feingold D.S., Lindahl U. Biosynthesis of heparin. Modulation of polysaccharide chain length in a cell-free system. Biochem. J. 1988, 254:571-578.
18. Linhardt R.J. Heparin: an important drug enters its seventh decades. Chem. Ind. 1991, 2:45-50.
19. Linhardt R.J., Liu J. Synthetic heparin. Curr. Opin. Pharmacol. 2012, 10.1016/j.coph.2011.12.002.
20. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat. Prod. Rep. 2009, 26:313-321.
21. Liu R., Liu J. Enzymatic synthesis of heparin. Sustain Biotechnol. 2010, 10:259-277.
22. Lu X.F., Vora H., Khosla C. Overproduction of free fatty acids in E. coli: implications for biodiesel production. Metab. Eng. 2008, 10:333-339.
23. Ly M., Wang Z.Y., Laremore T.N., Zhang F.M., Zhong W.H., Pu D., Zagorevski D.V., Dordick J.S., Linhardt R.J. Analysis of E. coli K5 capsular polysaccharide heparosan. Anal. Bioanal. Chem. 2011, 399:737-745.
24. Marino M., Banerjee M., Jonquieres R., Cossart P., Ghosh P. GW domains of the Listeria monocytogenes invasion protein InlB are SH3-like and mediate binding to host ligands. Embo. J. 2002, 21:5623-5634.
25. Manzoni M., Bergomi S., Cavazzoni V. Extracellular K5 polysaccharide of Escherichia coli: production and characterization. J. Bioact. Compat. Pol. 1993, 8:251-257.
26. Prasad S.B., Jayaraman G., Ramachandran K.B. Hyaluronic acid production is enhanced by the additional co-expression of UDP-glucose pyrophosphorylase in Lactococcus lactis. Appl. Microbiol. Biotechnol. 2010, 86:273-283.
27. Petit C., Rigg G.P., Pazzani C., Smith A., Sieberth V., Stevens M., Boulnois G., Jann K., Roberts I.S. Region 2 of the Escherichia coli K5 capsule gene cluster encoding proteins for the biosynthesis of the K5 polysaccharide. Mol. Micorobiol. 1995, 17:611-620.
28. Roman E., Roberts I., Lidholt K., Kusche-Gullberg M. Overexpression of UDP-Glucose dehydrogenase in Escherichia coli results in decreased biosynthesis of K5 polysaccharide. Biochem. J. 2003, 15:367-372.
29. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. second ed.
30. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer. 2002, 2:521-528.
31. Sugiura N., Baba Y., Kawaguchi Y., Iwatani T., Suzuki K., Kusakabe T., Yamagishi K., Kimata K., Kakuta Y., Watanabe H. Glucuronyltransferase activity of KfiC from Escherichia coli strain K5 requires association of KfiA. J. Biol. Chem. 2010, 285:1597-1606.
32. Tiwari V., Clement C., Duncan M.B., Chen J., Liu J., Shukla D. A role for 3-O-sulfated heparan sulfate in cell fusion induced by herpes simplex virus type I. J. Gen. Virol. 2004, 85:805-809.
33. Tyrell D.J., Kilfeather S., Page C.P. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol. Sci. 1995, 16:198-204.
34. Vann W.F., Schmidt M.A., Jann B., Jann K. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010-K5-H4-a polymer similar to desulfo-heparin. Eur. J. Biochem. 1981, 116:359-364.
35. Wang Z., Dordick, Jonathan S., Linhardt R.J. Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioengineered Bugs. 2011, 2:63-67.
36. Wang Z., Ly M., Zhang F.M., Zhong W.H., Suen A., Hickey A.M., Dordick J.S., Linhardt R.J. E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol. Bioeng. 2010, 107:964-973.
37. Wells M.A., Mercer J., Mott R.A., Pereira-Medrano A.G., Burja A.M., Radianingtyas H., Wright P.C. Engineering a non-native hydrogen production pathway into Escherichia coli via a cyanobacterial [NiFe] hydrogenase. Metab. Eng. 2011, 13:445-453.
38. Yu H., Stephanopoulos G. Metabolic engineering of Escherichia coli for biosynthesis of hyaluronic acid. Metab. Eng. 2007, 10:24-32.
39. Zhang Z.Q., McCallum S.A., Xie J., Nieto L., Corzana F., Jimenez-Barbero.J., Chen M., Liu J., Linhardtt R.J. Solution structures of chemoenzymatically synthesized heparin and its precursors. J. Am. Chem. Soc. 2008, 130:12998-13007.